Evoke Pharma, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Provided By GlobeNewswire
Last update: Mar 13, 2025
Q4 2024 revenue increased 24.6% over Q3 2024; Full-year 2024 revenue grew 97.8% year-over-year
Strong growth in key commercial metrics, including prescriber base, fill rates, and patient enrollments
Read more at globenewswire.comNASDAQ:EVOK (6/11/2025, 8:00:02 PM)
3
+0.15 (+5.26%)
Find more stocks in the Stock Screener
